The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Immortal time bias in a claims-database study

This is a generated summary. It shows the 5 most-liked posts from a topic of 35, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
MA
mi.almeidaTL214 Jul 2025#1

Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable.

Asking about immortal time bias directly, because I have read four threads on it and each answered a slightly different question.

The version I want answered is the narrow one: given the method stated below, is the result within what anyone else has seen? I am not asking what it means yet.

Method, numbers and the two assumptions I am aware of making are below. If the assumptions are wrong that is more useful to me than agreement.

54 likes 12mo
FW
f.wojcikTL21 Aug 2025#11
l.trevino, post #9: Generalisability and validity are separate axes. A trial can be internally impeccable and still tell you nothing about the person asking. That is what I would do. It may not be what is correct. Go to post

Taking post #8 at face value and following it one step further.

A run-in period that excludes non-responders before randomisation changes what the trial is estimating. It is legitimate design and it must be stated in any summary.

The reasoning is more useful than the number, which is why I have shown it.

27 likes in reply to #9 12mo
KK
k.karlsenTL221 Aug 2025#26
mi.almeida, post #1: Immortal time bias in a claims-database study — setting out what I have, and where I think it stops being reliable. Asking about immortal time bias directly, because I have read four threads on it and each answered a slightly different question. The version I want answered is the narrow one: given the method stated below, is the result… Go to post

Taking post #23 at face value and following it one step further.

Immortal time bias has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.

28 likes in reply to #1 11mo
F
FFaulknerTL3Regular24 Aug 2025#29
e.okafor, post #10: The arithmetic in post #7 is right; the assumption feeding it is the part to check. Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null. I looked this up rather than remembered it, which… Go to post

Post #28 describes the usual case. This is about the unusual one.

Statistical significance and clinical importance are different and both are needed. A significant difference below the minimal important difference is a real finding of no practical consequence.

The mechanism is plausible, which is not the same as established.

22 likes in reply to #10 11mo
EA
e.adeyemiTL230 Aug 2025#34
m.dalgaard, post #31: Small methodological point on immortal time bias: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone. Go to post

Where I part company with post #32, and it is a narrow parting.

Having read the whole immortal time bias thread before replying: the question in the first post has not actually been answered yet, and three of us have answered a nearby one instead.

30 likes in reply to #31 11mo

Read the full topic (35 posts)

This topic was closed 45 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
Critiquing an observational claim about a class effect
Posting this under the heading it deserves: Critiquing an observational claim about a class effect Everything below is what sits behind that. I was wrong about critiquing an observational claim in a thread…
VRRIJV 2 6.9k 14mo
A well-designed study with a badly written abstract
Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…
RCMICBMRPN+117 128 7.2k 14mo
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
TVARBDSBCD+21 25 21k 11mo
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I would like to disagree carefully with the settled view on claim built, and I…
ASKHMIASNP+71 80 1.1k 14mo
A structured critique template this community uses — a second dataset
On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Posting a small dataset on structured critique template. It is mine,…
PRFLKBACAW+47 51 16k 15h

Related topics — sharing the tags risk of bias, observational data, disputed

TopicParticipantsRepliesViewsActivity
Journal club: STEP-HFpEF and symptom endpoints — a second dataset
On the subject in the title: Journal club: STEP-HFpEF and symptom endpoints — a second dataset Working notes rather than a conclusion. Posting a small dataset on step-hfpef and symptom endpoints. It is mine,…
EDCRFKTVIA+11 15 4k 10mo
Journal club: STEP 8 and the fairness of the comparator dose — a second dataset
Posting this under the heading it deserves: Journal club: STEP 8 and the fairness of the comparator dose — a second dataset Everything below is what sits behind that. Posting a small dataset on STEP 8. It is…
OLIADSRFDO+18 22 656 13h
Follow-up: A supplier that answers analytical questions with restated claims
A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A follow-up question about supplier that I did not know to ask the first…
CCPYESTCB+74 82 2.8k 6mo
Journal club: semaglutide in MASH, and surrogate endpoints
Posting this under the heading it deserves: Journal club: semaglutide in MASH, and surrogate endpoints Everything below is what sits behind that. Working notes on semaglutide in MASH rather than a conclusion.…
MDSRSGSLSC+24 28 17k 15h
When a preprint is the best available evidence and we say so
When a preprint is the best available evidence and we say so — that is the question, and I have not found it answered plainly anywhere I have looked. A preprint question rather than a question about the…
CPNMKMJE+148 160 31k 11mo